Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...
pharmaphorum4h
Can Keytruda finally break into early head and neck cancer?
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
Cure Today3h
FDA Accepts sBLA For Opdivo Plus Yervoy For Some Patients with mCRC
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
Advanced Merkel Cell Carcinoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...
oncnursingnews4h
Supporting Patients Through Treatment for Upper GI Cancer Care
Experts discuss the role of supportive therapies, such as antiemetics, nutritional support, and physical activity, in improving outcomes and patient comfort during treatment.